Cargando…

Bezlotoxumab prevents extraintestinal organ damage induced by Clostridioides difficile infection

Clostridioides difficile is the most common cause of infectious antibiotic-associated diarrhea, with disease mediated by two major toxins TcdA and TcdB. In severe cases, systemic disease complications may arise, resulting in fatal disease. Systemic disease in animal models has been described, with t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mileto, Steven J., Hutton, Melanie L., Walton, Sarah L., Das, Antariksh, Ioannidis, Lisa J., Ketagoda, Don, Quinn, Kylie M., Denton, Kate M., Hansen, Diana S., Lyras, Dena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450906/ https://www.ncbi.nlm.nih.gov/pubmed/36045589 http://dx.doi.org/10.1080/19490976.2022.2117504

Ejemplares similares

Extraintestinal Clostridioides difficile infection
por: Hai, Zhao, et al.
Publicado: (2020)

Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection
por: Escudero-Sánchez, Rosa, et al.
Publicado: (2020)

Bezlotoxumab in the treatment of Clostridioides difficile infections: a real-life experience
por: Olmedo, María, et al.
Publicado: (2022)

Effectiveness of Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection Among Transplant Recipients
por: Johnson, Tanner M, et al.
Publicado: (2021)

Bezlotoxumab in Patients with a Primary Clostridioides difficile Infection: A Literature Review
por: Granata, Guido, et al.
Publicado: (2022)

729. Real World Efficacy of Bezlotoxumab for Prevention of Clostridioides Difficile Recurrence in Immunosuppressed Patients
por: Perreault, Sarah, et al.
Publicado: (2020)

Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection
por: de la Villa, Sofía, et al.
Publicado: (2023)

The Role of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infections: A Review of the Current Literature and Paradigm Shift after 2021
por: Hyte, Melanie L., et al.
Publicado: (2022)

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
por: Dubberke, Erik R, et al.
Publicado: (2020)

789. Evaluation of Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection in Patients at High Risk for Recurrence
por: Johnson, Tanner M, et al.
Publicado: (2020)

Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study
por: Hengel, Richard L, et al.
Publicado: (2020)

Bezlotoxumab for Preventing Recurrent Clostridioides difficile Infection: A Narrative Review from Pathophysiology to Clinical Studies
por: Giacobbe, Daniele Roberto, et al.
Publicado: (2020)

Exploratory Evaluation of Bezlotoxumab on Outcomes Associated With Clostridioides difficile Infection in MODIFY I/II Participants With Cancer
por: Cornely, Oliver A, et al.
Publicado: (2020)

1496. Bezlotoxumab Administered at the End of a Suppressive Drug Regimen for Patients with Multiply Recurrent Clostridioides difficile Infection
por: Tan, Xing, et al.
Publicado: (2019)

Double-Blind, Placebo-Controlled Study of Bezlotoxumab in Children Receiving Antibacterial Treatment for Clostridioides difficile Infection (MODIFY III)
por: Sferra, Thomas J, et al.
Publicado: (2023)

Extraintestinal Clostridioides difficile Infections: Epidemiology in a University Hospital in Hungary and Review of the Literature
por: Urbán, Edit, et al.
Publicado: (2020)

Efficacy of Bezlotoxumab Against Clostridioides difficile Infection: A Case-Series Study at a University Hospital in Japan and Literature Review
por: Mori, Nobuaki, et al.
Publicado: (2023)

Paeniclostridium sordellii and Clostridioides difficile encode similar and clinically relevant tetracycline resistance loci in diverse genomic locations
por: Vidor, Callum J., et al.
Publicado: (2019)

Extraintestinal Clostridioides difficile Infection (CDI): A Recurrent Battle with Resilient Abdominal Wall Abscess
por: Chinnappan, Justine, et al.
Publicado: (2023)

CdtR Regulates TcdA and TcdB Production in Clostridium difficile
por: Lyon, Shelley A., et al.
Publicado: (2016)

Disruption of the Gut Microbiome: Clostridium difficile Infection and the Threat of Antibiotic Resistance
por: Johanesen, Priscilla A., et al.
Publicado: (2015)

The Efficacy of Bezlotoxumab in the Prevention of Recurrent Clostridium difficile: A Systematic Review
por: Thandavaram, Abhay, et al.
Publicado: (2022)

Bezlotoxumab Therapy for Recurrent Clostridium difficile Infection in an Ulcerative Colitis Patient
por: Fein, Aaron, et al.
Publicado: (2022)

Cationic Peptidomimetic Amphiphiles Having a N-Aryl- or N-Naphthyl-1,2,3-Triazole Core Structure Targeting Clostridioides (Clostridium) difficile: Synthesis, Antibacterial Evaluation, and an In Vivo C. difficile Infection Model
por: Mahadari, Muni Kumar, et al.
Publicado: (2021)

Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative
por: Hutton, Melanie L., et al.
Publicado: (2017)

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence
por: Gerding, Dale N, et al.
Publicado: (2018)

Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection
por: Navalkele, Bhagyashri D, et al.
Publicado: (2018)

Genetic Association Reveals Protection against Recurrence of Clostridium difficile Infection with Bezlotoxumab Treatment
por: Shen, Judong, et al.
Publicado: (2020)

Bezlotoxumab for the prevention of Clostridium difficile infection: a review of current evidence and safety profile
por: Alonso, Carolyn D, et al.
Publicado: (2018)

Influence of Diagnostic Method on Outcomes in Phase 3 Clinical Trials of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: A Post Hoc Analysis of MODIFY I/II
por: Wilcox, Mark H, et al.
Publicado: (2019)

Analysis of C. difficile infection–related outcomes in European participants in the bezlotoxumab MODIFY I and II trials
por: Bouza, Emilio, et al.
Publicado: (2020)

Diagnostic Methods of Clostridioides difficile Infection and Clostridioides difficile Ribotypes in Studied Sample
por: Novakova, Elena, et al.
Publicado: (2021)

The Monoclonal Antitoxin Antibodies (Actoxumab–Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with Clostridium difficile Infection
por: Džunková, Mária, et al.
Publicado: (2016)

Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection
por: Prabhu, Vimalanand S, et al.
Publicado: (2017)

Multi-omics analysis of hospital-acquired diarrhoeal patients reveals biomarkers of enterococcal proliferation and Clostridioides difficile infection
por: Bosnjak, Marijana, et al.
Publicado: (2023)

Bezlotoxumab (BEZ) for Prevention of Clostridium Difficile Infection (CDI) Recurrence (rCDI): Outcomes in Patients with Substantial Renal Impairment (SRI)
por: Golan, Yoav, et al.
Publicado: (2017)

501. Evaluation of Bezlotoxumab in Prevention of Recurrent C. difficile Infection: A Multicenter Single-Arm Study in Outpatient Infusion Centers
por: Hengel, Richard L, et al.
Publicado: (2018)

Clostridioides difficile therapeutics: guidelines and beyond
por: Orenstein, Robert, et al.
Publicado: (2019)

505. Bezlotoxumab Reduces Recurrence of Clostridium difficile Infection in Immunocompromised Patients: Early Experience at a Tertiary Care Center
por: Askar, Sally, et al.
Publicado: (2018)

Clostridioides difficile Induced Rhabdomyolysis Associated With Decompensated Cirrhosis
por: Dungan, William, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p4rdj8lia872vueksppdnjs8b6